{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:22:39Z","timestamp":1765470159967,"version":"3.48.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":166,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurophysiology Practice"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.cnp.2025.06.004","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T14:52:54Z","timestamp":1750171974000},"page":"218-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Methotrexate-induced neurotoxicity: Diagnostic challenges and the role of neurophysiological testing"],"prefix":"10.1016","volume":"10","author":[{"given":"Pauline","family":"D\u2019hoore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joke","family":"Terryn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cnp.2025.06.004_b0005","doi-asserted-by":"crossref","unstructured":"Afshar M et al;. Review of dextromethorphan administration in 18 patients with subacute methotrexate central nervous system toxicity. Pediatr Neurol. 2014 Jun;50(6):625-9. doi: 10.1016\/j.pediatrneurol.2014.01.048. Epub 2014 Jan 31. Erratum in: Pediatr Neurol. 2014 Oct;51(4):593. PMID: 24742799.","DOI":"10.1016\/j.pediatrneurol.2014.01.048"},{"issue":"4","key":"10.1016\/j.cnp.2025.06.004_b0010","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/pbc.25850","article-title":"Rechallenging with intrathecal methotrexate after developing subacute neurotoxicity in children with hematologic malignancies","volume":"63","author":"Badke","year":"2016","journal-title":"Pediatr Blood Cancer."},{"key":"10.1016\/j.cnp.2025.06.004_b0015","unstructured":"Bhojwani D et al.; Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014 Mar 20;32(9):949-59. doi: 10.1200\/JCO.2013.53.0808. Epub 2014 Feb 18. PMID: 24550419; PMCID: PMC3948096."},{"issue":"1","key":"10.1016\/j.cnp.2025.06.004_b0020","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/hematology.2021000269","article-title":"Managing therapy-associated neurotoxicity in children with ALL","volume":"2021","author":"Bhojwani","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"4","key":"10.1016\/j.cnp.2025.06.004_b0025","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/leu.2012.328","article-title":"'Stroke-like syndrome' caused by intrathecal methotrexate in patients treated during the UKALL 2003 trial","volume":"27","author":"Bond","year":"2013","journal-title":"Leukemia."},{"issue":"12","key":"10.1016\/j.cnp.2025.06.004_b0030","doi-asserted-by":"crossref","first-page":"992","DOI":"10.7326\/0003-4819-110-12-992","article-title":"Selective vulnerability of the brain: new insights into the pathophysiology of stroke","volume":"110","author":"Collins","year":"1989","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.cnp.2025.06.004_b0035","doi-asserted-by":"crossref","unstructured":"Drachtman RA et al.; Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol. 2002 Jul-Aug;19(5):319-27. doi: 10.1080\/08880010290057336. PMID: 12078863.","DOI":"10.1080\/08880010290057336"},{"issue":"3","key":"10.1016\/j.cnp.2025.06.004_b0040","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3324\/haematol.2020.268565","article-title":"Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia","volume":"107","author":"Mateos","year":"2022","journal-title":"Haematologica."},{"issue":"4","key":"10.1016\/j.cnp.2025.06.004_b0045","doi-asserted-by":"crossref","first-page":"481","DOI":"10.29271\/jcpsp.2021.04.481","article-title":"Safety and efficacy of aminophylline in intrathecal methotrexate-related neurological toxicity in Large pediatric oncology Centre","volume":"31","author":"Razi","year":"2021","journal-title":"J Coll Physicians Surg Pak."},{"issue":"6","key":"10.1016\/j.cnp.2025.06.004_b0050","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Ponte di legno toxicity working group. consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus","volume":"17","author":"Schmiegelow","year":"2016","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.cnp.2025.06.004_b0055","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.bbr.2011.08.006","article-title":"Persistent cognitive deficits, induced by intrathecal methotrexate, are associated with elevated CSF concentrations of excitotoxic glutamate analogs and can be reversed by an NMDA antagonist","volume":"225","author":"Vijayanathan","year":"2011","journal-title":"Behav Brain Res."}],"container-title":["Clinical Neurophysiology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2467981X25000277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2467981X25000277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:17:44Z","timestamp":1765469864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2467981X25000277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":11,"alternative-id":["S2467981X25000277"],"URL":"https:\/\/doi.org\/10.1016\/j.cnp.2025.06.004","relation":{},"ISSN":["2467-981X"],"issn-type":[{"type":"print","value":"2467-981X"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methotrexate-induced neurotoxicity: Diagnostic challenges and the role of neurophysiological testing","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurophysiology Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cnp.2025.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of International Federation of Clinical Neurophysiology.","name":"copyright","label":"Copyright"}]}}